Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.51 USD
Change Today -0.26 / -2.41%
Volume 11.1M
NVAX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Open
$10.38
Previous Close
$10.77
Day High
$10.61
Day Low
$10.08
52 Week High
08/11/15 - $15.01
52 Week Low
10/2/14 - $3.92
Market Cap
2.8B
Average Volume 10 Days
5.8M
EPS TTM
$-0.39
Shares Outstanding
269.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, as well as pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, as well as rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

356 Employees
Last Reported Date: 08/10/15
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $487.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $389.8K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $291.7K
Compensation as of Fiscal Year 2014.

novavax inc (NVAX) Key Developments

Novavax, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Novavax, Inc. announced earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, the company reported net loss of $20.6 million or $0.08 per share compared to a net loss of $17.9 million or $0.08 per share a year ago. Revenue in the second quarter of 2015 increased 69% to $14.0 million compared to $8.3 million for the same period in 2014. This increase results from the recovery of additional costs under the HHS BARDA contract for the settlement of indirect rates for fiscal years 2011 and 2012, resulting in an additional $7.7 million in revenue for the quarter. For the six months, the company reported net loss was $45.0 million or $0.18 per share, compared to a net loss of $31.7 million or $0.15 per share a year ago. Net cash used in operating activities for the six months of 2015 was $42.8 million, compared to $31.4 million for the same period in 2014. The factors contributing to the change in operating cash usage were primarily due to increased costs relating to RSV F Vaccine, Ebola GP Vaccine and higher employee-related expenses, as well as the timing of customer and vendor payments.

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults

Novavax, Inc. announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate in older adults. The RSV F Vaccine was well-tolerated and fulfilled the company's expectations of the primary, secondary and exploratory objectives of the trial. The Novavax trial was a randomized, observer-blinded, placebo-controlled Phase 2 trial of 1,600 older adult participants conducted at 10 sites in the United States. The trial was designed to prospectively examine the incidence of all symptomatic respiratory illnesses associated with RSV, in community-living older adults who were treated with placebo. The trial also evaluated safety and immunogenicity of the unadjuvanted, 135Â microgram dose of the RSV F Vaccine compared to placebo. Finally, the trial estimated the efficacy of the RSV F Vaccine in reducing the incidence of respiratory illness due to RSV. The trial is the first to demonstrate efficacy of an active RSV immunization in any clinical trial population, and showed statistically significant vaccine efficacy in prevention of all symptomatic RSV disease (44%) and RSV disease with symptoms of lower respiratory tract infection (46%) in older adults. The observed efficacy was similar to or better than multiple recent effectiveness estimates for a number of licensed respiratory vaccines tested in older adults including pneumococcal and standard-dose seasonal influenza.1,2. The trial also established an attack rate for symptomatic RSV disease of 4.9% in older adults, 95% of which included lower respiratory track symptoms, and confirmed the significant burden of RSV disease in this population. In addition, statistically significant efficacy against more severe RSV illness, as defined by the presence of multiple lower respiratory tract symptoms associated with difficulty breathing, was 64% in several ad hoc analyses. Kaplan-Meier curves showed continued divergence of active vaccinees from placebo recipients over the nearly 6 months during which RSV was detected, demonstrating the durability of protection throughout the RSV season. As expected from the company's prior trials, anti-F IgG and palivizumab-competing antibody titers peaked rapidly at day 14, plateaued at day 28 and remained at elevated levels through day 56; the last time point currently analyzed. There were greater than four-fold increases in both anti-F IgG and PCA concentrations at trial days 14, 28 and 56, and serologic responses in over 90% of vaccinated subjects, indicating a robust immune response, similar to the findings from the company's prior trial in older adults. Finally, the safety profile in vaccine recipients was nearly identical to that of placebo recipients with regard to both local and systemic events.

Novavax, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Novavax, Inc. announced that they will report Q2, 2015 results at 4:45 PM, US Eastern Standard Time on Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $10.51 USD -0.26

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $19.11 USD -0.25
Dynavax Technologies Corp $27.10 USD -1.26
Inovio Pharmaceuticals Inc $7.10 USD -0.39
Progenics Pharmaceuticals Inc $7.10 USD -0.23
ZIOPHARM Oncology Inc $8.57 USD -0.14
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.3x
Price/Book 8.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 72.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.